Key result
Xuefu Zhuyu Decoction shifts plasma metabolomic profiles in coronary disease, increasing lipids and reducing lactate.
Why the study?
The study sought to establish metabolic fingerprints and identify potential biomarker metabolites of CHD with blood-stasis syndrome and phlegm syndrome, and to reveal the metabolic mechanism of Xuefu Zhuyu Decoction.
Does Xuefu Zhuyu Decoction alter plasma metabolic biomarkers in patients with coronary heart disease and blood-stasis syndrome?
Observational (n=169)
Does Xuefu Zhuyu Decoction alter plasma metabolic biomarkers in patients with coronary heart disease and blood-stasis syndrome?
1H-NMR metabolomics identified distinct biomarker profiles for CHD blood-stasis and phlegm syndromes, and demonstrated that Xuefu Zhuyu Decoction alters lipid and energy metabolism in blood-stasis syndrome.
Metabolomic biomarkers may refine TCM syndrome classification in CHD; hypothesis-generating for Xuefu Zhuyu Decoction effects, requiring RCTs before practice change.
Objectives Coronary heart disease (CHD) is a serious threat to human health because of its high morbidity. It is very urgent to study the pathogenesis of CHD and the effective drug target. The purpose of this paper is using the 1H-nuclear magnetic resonance spectroscopy (1H-NMR) metabolomics technology to establish the metabolic fingerprint and find the potential biomarker metabolites of CHD with blood-stasis syndrome and phlegm syndrome, and to reveal the metabolic mechanism of Xuefu Zhuyu Decoction for the treatment of CHD with blood stasis syndrome. Methods The plasma samples of 69 patients with CHD blood-stasis syndrome, 60 patients with CHD phlegm syndrome, and 40 healthy volunteers were collected in this study. Based on the 1H-NMR metabolomics technology, the metabolic fingerprint of CHD with blood-stasis syndrome and phlegm syndrome was established. Multivariate statistical analysis methods including principal component analysis (PCA) and orthogonal partial least squares-discriminant analysis (OPLS-DA) were used to find the potential biomarker metabolites of CHD with blood-stasis syndrome and phlegm syndrome. Xuefu Zhuyu Decoction was used to randomly selected blood-stasis syndrome patient. The plasma samples of pre-treatment and post-treatment were collected. 1H-NMR and multivariate statistical analysis were used to analyze the changes of metabolites in patients with CHD blood-stasis syndrome before and after Xuefu Zhuyu Decoction treatment. Results A total of 15 potential biomarkers were identified in the plasma of patients with CHD blood-stasis syndrome, including 3-hydroxybutyrate (3-HB), lactate, alanine, glutamate, glutamine, pyruvate,phosphatidylcholine (PC), glycerylphosphorylcholine (GPC), glycine, glucose, phenylalanine, citrate,tyrosine, formate,very low density lipoprotein (VLDL). The levels of glucose, 3-HB, and VLDL increased, while the levels of other 12 metabolites decreased. A total of 16 potential biomarkers were identified in the plasma of patients with CHD phlegm syndrome, including valine, lactate, alanine, N-acetyl-β-glucosaminidase (NAG), glutamate, glutamine, pyruvate, creatine, choline, glycine, glucose, phenylalanine, citrate, histidine, tyrosine, and formate. The levels of glucose and choline increased, while the levels of other 12 metabolites decreased. After treatment with Xuefu Zhuyu Decoction, the levels of choline, phospholipids/glycerolipids, creatine, lipids, and citrate increased, while the level of lactate decreased in patients with CHD blood-stasis syndrome. Conclusions 1H-NMR combined with multivariate statistical method could effectively establish the diagnostic model for CHD blood-stasis syndrome and CHD phlegm syndrome, and find the metabolites related to the syndrome type. The metabolic mechanism of Xuefu Zhuyu Decoction on CHD blood-stasis syndrome may be associated with regulation of lipid metabolism and energy metabolism.
No takes yet. Share an insight, caveat, or question.
Yi et al. (2021) conducted an observational in Coronary heart disease with blood-stasis syndrome or phlegm syndrome (n=169). 1H-NMR metabolomics profiling and Xuefu Zhuyu Decoction vs. Healthy volunteers and pre-treatment baseline was evaluated on Identification of plasma biomarker metabolites and metabolic profile changes. 1H-NMR metabolomics identified 15 plasma biomarkers in CHD blood-stasis syndrome and 16 in phlegm syndrome, while Xuefu Zhuyu Decoction increased choline, citrate, and lipids and reduced lactate.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: